RHOA and breast cancer: For example, Y16 was identified to specifically inhibit RHOA activation through disrupting Rho GEF LARG binding to RhoA.401 LM11, a noncompetitive ARF1 inhibitor, targets the binding of ARF1 to GEF ARNO at the Golgi and significantly decreased metastatic capability of breast cancer cells in a zebrafish model.351,402 Similar to quinazoline inhibitors binding to SOS1, Sec7 inhibitor H3 (SecinH3) can also disrupt the interaction of ARF1 and ARF6 with ARNO by inhibiting the Sec7 catalytic domain in ARNO.